C. difficile infection (CDI) poses a significant and increasing threat¹^,²

INCREASING RATES OF CDI INCIDENCE AND MORTALITY IN THE UNITED STATES^3,4

Number of CDI Cases and Rate of C. Difficile-Related Mortality

Incidence and severity of CDI cases are increasing, with approximately 700,000 new cases per year in the United States^1,2,5,6
CDI accounts for significant rates of morbidity and mortality that increase with patient age, with a mortality rate as high as 14% in elderly patients⁷
C. difficile is the most common cause of infectious diarrhea in healthcare settings⁸
C. difficile-associated diarrhea (CDAD) is the most common symptom of CDI⁸
Rising incidence of CDAD attributed to widespread use of broad-spectrum antibiotics⁸
Treatment failure rates ranged from 3% to 4% pre-2000, and 3% to 18% post-2000⁹
Community-acquired infection threatens populations previously considered to be at low risk¹⁰
Since 2000, C. difficile epidemiology has evolved to include a hypervirulent strain with possible increased toxin production and sporulation^11-13

ACCORDING TO THE CDC, CDI RATES INCREASED 200% FOR
HOSPITALIZED PATIENTS AGED ≥65 YEARS FROM 1996-2009¹⁴

Important Safety Information

DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin
DIFICID should not be used for systemic infections
Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported. In the event of a severe reaction, discontinue DIFICID.
Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile.
Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug- resistant bacteria.
The most common adverse reactions reported in clinical trials are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%)

Indications and Usage

DIFICID is a macrolide antibacterial drug indicated in adults ≥18 years of age for treatment of Clostridium difficile-associated diarrhea
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridium difficile

10. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7(7):526-536.

11. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433-2441.